0001493152-24-000115.txt : 20240102
0001493152-24-000115.hdr.sgml : 20240102
20240102170022
ACCESSION NUMBER: 0001493152-24-000115
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231228
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FR Capital Holdings, L.P.
CENTRAL INDEX KEY: 0001776703
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36581
FILM NUMBER: 24503306
BUSINESS ADDRESS:
STREET 1: 2400 MARKET STREET
STREET 2: SUITE 237
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 610-834-1461
MAIL ADDRESS:
STREET 1: 2400 MARKET STREET
STREET 2: SUITE 237
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Notable Labs, Ltd.
CENTRAL INDEX KEY: 0001603207
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 320 HATCH DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 415-851-2410
MAIL ADDRESS:
STREET 1: 320 HATCH DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: Vascular Biogenics Ltd.
DATE OF NAME CHANGE: 20140320
4
1
ownership.xml
X0508
4
2023-12-28
0
0001603207
Notable Labs, Ltd.
NTBL
0001776703
FR Capital Holdings, L.P.
2400 MARKET STREET,
SUITE 237
PHILADELPHIA
PA
19103
0
0
1
0
0
Ordinary Shares, par value NIS 0.35 each
2023-12-28
4
S
0
21500
2.0068
D
936489
I
See Footnote
Ordinary Shares, par value NIS 0.35 each
2023-12-29
4
S
0
6000
1.8316
D
930489
I
See Footnote
FR Capital Holdings, L.P. (the "Reporting Person") is the investment manager to First Round Capital V, LP, a Delaware limited partnership ("FRCV"), and First Round Capital VIII-F, LP, a Delaware limited partnership ("FRCVIIIF"). Josh Kopelman and William Trenchard are the managing members of the Reporting Person. As of January 2, 2024, FRCV held 381,971 ordinary shares, par value NIS 0.35 each ("Ordinary Shares") of Notable Labs, Ltd. and FRCVIIIF held 549,985 Ordinary Shares. The Reporting Person's and Messrs. Kopelman and Trenchard's beneficial ownership is limited to their pecuniary interest, if any, in such securities.
On December 28, 2023, FRCV sold 7,977 Ordinary Shares and FRCVIIIF sold 13,523 Ordinary shares, each at a weighted average price of $2.0068 per share. These shares were sold in multiple transactions at prices ranging from $1.92 to $2.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On December 29, 2023, FRCV sold 2,224 Ordinary Shares and FRCVIIIF sold 3,776 Ordinary shares, each at a weighted average price of $1.8316 per share. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.8601, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jeffrey Donnon, Chief Financial Officer of FR Capital Holdings, L.P.
2024-01-02